{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:04:46Z","timestamp":1769000686826,"version":"3.49.0"},"reference-count":180,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia (FCT) and FEDER","award":["LISBOA-01-0145-FEDER-028534"],"award-info":[{"award-number":["LISBOA-01-0145-FEDER-028534"]}]},{"name":"FCT - Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","award":["UID\/BIM\/04501\/2019"],"award-info":[{"award-number":["UID\/BIM\/04501\/2019"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Despite improvements in cancer therapy, metastatic solid tumors remain largely incurable. Immunotherapy has emerged as a pioneering and promising approach for cancer therapy and management, and in particular intended for advanced tumors unresponsive to current therapeutics. In cancer immunotherapy, components of the immune system are exploited to eliminate cancer cells and treat patients. The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer treatment. Despite their potential success, current approaches depend on efficient tumor antigen presentation which are often inaccessible, and most tumors turn refractory to current immunotherapy. Patient-derived induced pluripotent stem cells (iPSCs) have been shown to share several characteristics with cancer (stem) cells (CSCs), eliciting a specific anti-tumoral response when injected in rodent cancer models. Indeed, artificial cellular reprogramming has been widely compared to the biogenesis of CSCs. Here, we will discuss the state-of-the-art on the potential implication of cellular reprogramming and iPSCs for the design of patient-specific immunotherapeutic strategies, debating the similarities between iPSCs and cancer cells and introducing potential strategies that could enhance the efficiency and therapeutic potential of iPSCs-based cancer vaccines.<\/jats:p>","DOI":"10.3390\/cancers12123581","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T20:10:22Z","timestamp":1606767022000},"page":"3581","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6407-3466","authenticated-orcid":false,"given":"Bruno","family":"Bernardes de Jesus","sequence":"first","affiliation":[{"name":"Department of Medical Sciences and Institute of Biomedicine\u2014iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-3124","authenticated-orcid":false,"given":"Bruno Miguel","family":"Neves","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Institute of Biomedicine\u2014iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9498-8061","authenticated-orcid":false,"given":"Manuela","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Center for Neuroscience and Cell Biology (CNC), University of Coimbra, UC Biotech, Biocant Park, 3060-197 Cantanhede, Portugal"},{"name":"Champalimaud Research, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9652-1382","authenticated-orcid":false,"given":"Sandrina","family":"N\u00f3brega-Pereira","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Institute of Biomedicine\u2014iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal"},{"name":"Instituto de Medicina Molecular Jo\u00e3o Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"ref_1","first-page":"6261721","article-title":"Cancer-associated immune resistance and evasion of immune surveillance in colorectal cancer","volume":"2016","author":"Parcesepe","year":"2016","journal-title":"Gastroenterol. Res. Pr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.tibtech.2014.06.007","article-title":"Towards efficient cancer immunotherapy: Advances in developing artificial antigen-presenting cells","volume":"32","author":"Eggermont","year":"2014","journal-title":"Trends Biotechnol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41568-018-0067-7","article-title":"New targets for cancer immunotherapy","volume":"18","author":"Dart","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: Harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cell.2015.02.045","article-title":"Modeling familial cancer with induced pluripotent stem cells","volume":"161","author":"Lee","year":"2015","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: The CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imr.12126","article-title":"CAR T cells: Driving the road from the laboratory to the clinic","volume":"257","author":"Cheadle","year":"2014","journal-title":"Immunol. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","article-title":"Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology","volume":"39","author":"Kalos","year":"2013","journal-title":"Immunity"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2018.00367","article-title":"The role of natural killer T cells in cancer\u2014A phenotypical and functional approach","volume":"9","author":"Krijgsman","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1158\/2159-8290.CD-13-0985","article-title":"T-cell and NK-cell infiltration into solid tumors: A key limiting factor for efficacious cancer immunotherapy","volume":"4","author":"Melero","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/08830185.2015.1015888","article-title":"A new era in cancer immunotherapy: Discovering novel targets and reprogramming the immune system","volume":"34","author":"Bot","year":"2015","journal-title":"Int. Rev. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-800267-4.00003-1","article-title":"Recognition of tumors by the innate immune system and natural killer cells","volume":"122","author":"Marcus","year":"2014","journal-title":"Adv. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/734515","article-title":"Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy","volume":"2014","author":"Escors","year":"2014","journal-title":"New J. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","article-title":"UVB-Induced tumor heterogeneity diminishes immune response in melanoma","volume":"179","author":"Wolf","year":"2019","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41577-019-0230-8","article-title":"Tumour heterogeneity determines immune response","volume":"19","author":"Flemming","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/stem.3095","article-title":"Induced pluripotent stem cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy","volume":"38","author":"Horton","year":"2020","journal-title":"Stem Cells"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1038\/s41598-018-23120-z","article-title":"Cancer vaccine therapy using carcinoembryonic antigen\u2014Expressing dendritic cells generated from induced pluripotent stem cells","volume":"8","author":"Kitadani","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.celrep.2019.08.086","article-title":"Type I interferon delivery by iPSC-derived myeloid cells elicits antitumor immunity via XCR1+ dendritic cells","volume":"29","author":"Tsuchiya","year":"2019","journal-title":"Cell Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2016.01.005","article-title":"Cellular adjuvant properties, direct cytotoxicity of re-differentiated V\u03b124 invariant NKT-like cells from human induced pluripotent stem cells","volume":"6","author":"Kitayama","year":"2016","journal-title":"Stem Cell Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nbt.2678","article-title":"Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy","volume":"31","author":"Themeli","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.stemcr.2018.04.025","article-title":"Generation of TCR-expressing innate lymphoid-like helper cells that induce cytotoxic T cell-mediated anti-leukemic cell response","volume":"10","author":"Ueda","year":"2018","journal-title":"Stem Cell Rep."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.3389\/fimmu.2019.02809","article-title":"Understanding and modulating immunity with cell reprogramming","volume":"10","author":"Pires","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.exphem.2018.12.005","article-title":"Development of innate immune cells from human pluripotent stem cells","volume":"71","author":"Bernareggi","year":"2019","journal-title":"Exp. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11899-019-00528-6","article-title":"Induced pluripotent stem cell (iPSC)\u2013derived lymphocytes for adoptive cell immunotherapy: Recent advances and challenges","volume":"14","author":"Nianias","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","article-title":"Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors","volume":"126","author":"Takahashi","year":"2006","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1126\/science.1151526","article-title":"Induced pluripotent stem cell lines derived from human somatic cells","volume":"318","author":"Yu","year":"2007","journal-title":"Science"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.stem.2020.09.014","article-title":"Pluripotent stem cell-based cell therapy-promise and challenges","volume":"27","author":"Yamanaka","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1038\/s41467-018-05059-x","article-title":"AAVvector-mediated in vivo reprogramming into pluripotency","volume":"9","author":"Mosteiro","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2011.06.007","article-title":"Epigenetic memory and preferential lineage-specific differentiation in induced pluripotent stem cells derived from human pancreatic islet beta cells","volume":"9","author":"Russ","year":"2011","journal-title":"Cell Stem Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.stem.2016.06.019","article-title":"Epigenetic variation between human induced pluripotent stem cell lines is an indicator of differentiation capacity","volume":"19","author":"Nishizawa","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nbt.2052","article-title":"Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells","volume":"29","author":"Kim","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12538","DOI":"10.1073\/pnas.1209979109","article-title":"Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells","volume":"109","author":"Kajiwara","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nature09805","article-title":"Somatic coding mutations in human induced pluripotent stem cells","volume":"471","author":"Gore","year":"2011","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1038\/ncomms5825","article-title":"Aneuploidy induces profound changes in gene expression, proliferation and tumorigenicity of human pluripotent stem cells","volume":"5","author":"Arad","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.stem.2019.09.001","article-title":"Cancer-related mutations identified in primed and naive human pluripotent stem cells","volume":"25","author":"Avior","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.stem.2012.02.013","article-title":"Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives","volume":"10","author":"Nazor","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature09798","article-title":"Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells","volume":"471","author":"Lister","year":"2011","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/nbt.1667","article-title":"Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells","volume":"28","author":"Polo","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/ncb2239","article-title":"Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells","volume":"13","author":"Ohi","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature09017","article-title":"Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells","volume":"465","author":"Stadtfeld","year":"2010","journal-title":"Nature"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/stem.793","article-title":"Status of genomic imprinting in epigenetically distinct pluripotent stem cells","volume":"30","author":"Sun","year":"2012","journal-title":"Stem Cells"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.scr.2013.05.011","article-title":"Genomic imprinting is variably lost during reprogramming of mouse iPS cells","volume":"11","author":"Takikawa","year":"2013","journal-title":"Stem Cell Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.stemcr.2019.04.008","article-title":"De novo DNA methylation at imprinted loci during reprogramming into naive and primed pluripotency","volume":"12","author":"Yagi","year":"2019","journal-title":"Stem Cell Reports"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.celrep.2017.04.020","article-title":"Large-scale analysis of loss of imprinting in human pluripotent stem cells","volume":"19","author":"Bar","year":"2017","journal-title":"Cell Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/stem.475","article-title":"Major histocompatibility complex-I expression on embryonic stem cell-derived vascular progenitor cells is critical for syngeneic transplant survival","volume":"28","author":"Ma","year":"2010","journal-title":"Stem Cells"},{"key":"ref_51","first-page":"328","article-title":"Reprogramming in vivo produces teratomas and iPS cells with totipotency features","volume":"471","author":"Ji","year":"2013","journal-title":"Nature"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nature22403","article-title":"Common genetic variation drives molecular heterogeneity in human iPSCs","volume":"546","author":"Kilpinen","year":"2017","journal-title":"Nature"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-019-1658-5","article-title":"Heterogeneity in old fibroblasts is linked to variability in reprogramming and wound healing","volume":"574","author":"Mahmoudi","year":"2019","journal-title":"Nature"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1073\/pnas.1103388108","article-title":"Genetic correction and analysis of induced pluripotent stem cells from a patient with gyrate atrophy","volume":"108","author":"Howden","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.stem.2011.07.018","article-title":"Genome sequencing of mouse induced pluripotent stem cells reveals retroelement stability and infrequent DNA rearrangement during reprogramming","volume":"9","author":"Quinlan","year":"2011","journal-title":"Cell Stem Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature11629","article-title":"Somatic copy number mosaicism in human skin revealed by induced pluripotent stem cells","volume":"492","author":"Abyzov","year":"2012","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.stem.2012.01.005","article-title":"Low incidence of DNA sequence variation in human induced pluripotent stem cells generated by nonintegrating plasmid expression","volume":"10","author":"Cheng","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.stem.2013.07.001","article-title":"Genetic and epigenetic variations in iPSCs: Potential causes and implications for application","volume":"13","author":"Liang","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.stem.2012.03.002","article-title":"Background mutations in parental cells account for most of the genetic heterogeneity of induced pluripotent stem cells","volume":"10","author":"Young","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-030-11096-3_6","article-title":"Pluripotent stem cell heterogeneity","volume":"1123","author":"Hayashi","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1093\/hmg\/ddv201","article-title":"Mitochondrial respiratory dysfunction caused by a heteroplasmic mitochondrial DNA mutation blocks cellular reprogramming","volume":"24","author":"Yokota","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"945","DOI":"10.18632\/aging.100950","article-title":"Study of mitochondrial respiratory defects on reprogramming to human induced pluripotent stem cells","volume":"8","author":"Hung","year":"2016","journal-title":"Aging"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature12923","article-title":"Cell-autonomous correction of ring chromosomes in human induced pluripotent stem cells","volume":"507","author":"Bershteyn","year":"2014","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10114","DOI":"10.1038\/srep10114","article-title":"Chromosome microduplication in somatic cells decreases the genetic stability of human reprogrammed somatic cells and results in pluripotent stem cells","volume":"5","author":"Yu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.stemcr.2013.11.006","article-title":"Induced pluripotent stem cell generation-associated point mutations arise during the initial stages of the conversion of these cells","volume":"2","author":"Sugiura","year":"2014","journal-title":"Stem Cell Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.celrep.2017.09.060","article-title":"Hotspots of de novo point mutations in induced pluripotent stem cells","volume":"21","author":"Yoshihara","year":"2017","journal-title":"Cell Rep."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Rouhani, F.J., Nik-Zainal, S., Wuster, A., Li, Y., Conte, N., Koike-Yusa, H., Kumasaka, N., Vallier, L., Yusa, K., and Bradley, A. (2016). Mutational history of a human cell lineage from somatic to induced pluripotent stem cells. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1005932"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/nbt.1615","article-title":"High-resolution DNA analysis of human embryonic stem cell lines reveals culture-induced copy number changes and loss of heterozygosity","volume":"28","author":"Autio","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/978-1-4419-7037-4_9","article-title":"Telomeres and telomerase in adult stem cells and pluripotent embryonic stem cells","volume":"695","author":"Marion","year":"2010","journal-title":"Adv. Exp. Med. Biol"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.stem.2008.12.010","article-title":"Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells","volume":"4","author":"Marion","year":"2009","journal-title":"Cell Stem Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.tig.2013.06.007","article-title":"Telomerase at the intersection of cancer and aging","volume":"29","author":"Blasco","year":"2013","journal-title":"Trends Genet."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41576-019-0100-z","article-title":"Induced pluripotent stem cells in disease modelling and drug discovery","volume":"20","author":"Rowe","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature12586","article-title":"Reprogramming in vivo produces teratomas and iPS cells with totipotency features","volume":"502","author":"Abad","year":"2013","journal-title":"Nature"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine learning identifies stemness features associated with oncogenic dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nature08802","article-title":"Heteroplasmic mitochondrial DNA mutations in normal and tumour cells","volume":"464","author":"He","year":"2010","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.01510","article-title":"Induced pluripotent stem cell-based cancer vaccines","volume":"10","author":"Ouyang","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00704377","article-title":"The ultrastructural immunohistochemistry of oncofoetal antigens in large bowel carcinomas","volume":"405","author":"Haynes","year":"1985","journal-title":"Virchows Arch. A"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1158\/0008-5472.CAN-10-4402","article-title":"Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells","volume":"71","author":"Ghosh","year":"2011","journal-title":"Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.stem.2018.01.016","article-title":"Autologous iPSC-based vaccines elicit anti-tumor responses in vivo","volume":"22","author":"Kooreman","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.cell.2016.08.008","article-title":"Cellular metabolism and induced pluripotency","volume":"166","author":"Wu","year":"2016","journal-title":"Cell"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s42255-019-0032-0","article-title":"Metabolic signatures of cancer cells and stem cells","volume":"1","author":"Intlekofer","year":"2019","journal-title":"Nat. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1158\/0008-5472.CAN-15-0491","article-title":"Tumors and mitochondrial respiration: A neglected connection","volume":"75","author":"Viale","year":"2015","journal-title":"Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cmet.2011.06.011","article-title":"Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming","volume":"14","author":"Folmes","year":"2011","journal-title":"Cell Metab."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/cr.2011.177","article-title":"The metabolome of induced pluripotent stem cells reveals metabolic changes occurring in somatic cell reprogramming","volume":"22","author":"Panopoulos","year":"2012","journal-title":"Cell Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41556-020-0525-9","article-title":"Extracellular serine controls epidermal stem cell fate and tumour initiation","volume":"22","author":"Baksh","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.15252\/embj.201695417","article-title":"Fatty acid synthesis is critical for stem cell pluripotency via promoting mitochondrial fission","volume":"36","author":"Wang","year":"2017","journal-title":"EMBO J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.stem.2019.05.001","article-title":"Lipid deprivation induces a stable, naive-to-primed intermediate state of pluripotency in human PSCs","volume":"25","author":"Cornacchia","year":"2019","journal-title":"Cell Stem Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40880-019-0393-5","article-title":"Cancer cell reprogramming: A promising therapy converting malignancy to benignity","volume":"39","author":"Gong","year":"2019","journal-title":"Cancer Commun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"4598195","DOI":"10.1155\/2018\/4598195","article-title":"Tumorigenic cell reprogramming and cancer plasticity: Interplay between signaling, microenvironment, and epigenetics","volume":"2018","author":"Poli","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"key":"ref_93","first-page":"1","article-title":"Modeling cancer using patient-derived induced pluripotent stem cells to understand development of childhood malignancies","volume":"4","author":"Susanto","year":"2018","journal-title":"Cell Death Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/nature08287","article-title":"A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity","volume":"460","author":"Marion","year":"2009","journal-title":"Nature"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nature08290","article-title":"The Ink4\/Arf locus is a barrier for iPS cell reprogramming","volume":"460","author":"Li","year":"2009","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Qi, S., Song, Y., Peng, Y., Wang, H., Long, H., Yu, X., Li, Z., Fang, L., Wu, A., and Luo, W. (2012). ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0038842"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/stem.2521","article-title":"Zeb2 regulates cell fate at the exit from epiblast state in mouse embryonic stem cells","volume":"35","author":"Stryjewska","year":"2017","journal-title":"Stem Cells"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Santos, F., Moreira, C., Nobrega-Pereira, S., and Bernardes de Jesus, B. (2019). New insights into the role of epithelial-mesenchymal transition during aging. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040891"},{"key":"ref_99","first-page":"1","article-title":"Silencing of the lncRNA Zeb2-NAT facilitates reprogramming of aged fibroblasts and safeguards stem cell pluripotency","volume":"9","author":"Marinho","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature05934","article-title":"Generation of germline-competent induced pluripotent stem cells","volume":"448","author":"Okita","year":"2007","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/stem.1011","article-title":"Elevated coding mutation rate during the reprogramming of human somatic cells into induced pluripotent stem cells","volume":"30","author":"Ji","year":"2012","journal-title":"Stem Cells"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/s41587-019-0227-7","article-title":"De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-018-0426-4","article-title":"Cancer stem cells as key drivers of tumour progression","volume":"25","author":"Ayob","year":"2018","journal-title":"J. Biomed. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1073\/pnas.1102454108","article-title":"Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state","volume":"108","author":"Chaffer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases\u2014Elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: Integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: From immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/gm291","article-title":"Embryonic stem cell-specific signatures in cancer: Insights into genomic regulatory networks and implications for medicine","volume":"3","author":"Kim","year":"2011","journal-title":"Genome Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.cell.2010.12.032","article-title":"Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines","volume":"144","author":"Bock","year":"2011","journal-title":"Cell"},{"key":"ref_111","first-page":"2517","article-title":"Untersuchungen \u00fcber Karzinomimmunit\u00e4t bei M\u00e4usen","volume":"51","year":"1906","journal-title":"M\u00fcnch. Med. Wochenschr"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.yexmp.2008.12.002","article-title":"Embryonic vaccines against cancer: An early history","volume":"86","author":"Brewer","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s12015-020-10042-5","article-title":"Tumorigenic and immunogenic properties of induced pluripotent stem cells: A promising cancer vaccine","volume":"16","author":"Qiao","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1002\/stem.234","article-title":"Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer","volume":"27","author":"Li","year":"2009","journal-title":"Stem Cells"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nature10135","article-title":"Immunogenicity of induced pluripotent stem cells","volume":"474","author":"Zhao","year":"2011","journal-title":"Nature"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"G\u0105bka-Buszek, A., Kwiatkowska-Borowczyk, E., Jankowski, J., Koz\u0142owska, A.K., and Mackiewicz, A. (2020). Novel genetic melanoma vaccines based on induced pluripotent stem cells or melanosphere-derived stem-like cells display high efficacy in a murine tumor rejection model. Vaccines, 8.","DOI":"10.3390\/vaccines8020147"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/1759-7714.13440","article-title":"Expression levels of a gene signature in hiPSC associated with lung adenocarcinoma stem cells and its capability in eliciting specific antitumor immune-response in a humanized mice model","volume":"11","author":"Wang","year":"2020","journal-title":"Thorac. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1158\/1078-0432.CCR-19-1395","article-title":"A virus-infected, reprogrammed somatic cell-derived tumor cell (VIReST) vaccination regime can prevent initiation and progression of pancreatic cancer","volume":"26","author":"Lu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_120","first-page":"1","article-title":"Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance","volume":"5","author":"Meyer","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1096\/fj.09-134957","article-title":"Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells","volume":"24","author":"Dressel","year":"2010","journal-title":"FASEB J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.it.2015.11.005","article-title":"Understanding stem cell immunogenicity in therapeutic applications","volume":"37","author":"Wood","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1089\/scd.2006.15.254","article-title":"Growth of teratomas derived from human pluripotent stem cells is influenced by the graft site","volume":"15","author":"Cooke","year":"2006","journal-title":"Stem Cells Dev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCRESAHA.111.249243","article-title":"Immunogenicity of pluripotent stem cells and their derivatives","volume":"112","author":"Ransohoff","year":"2013","journal-title":"Circ. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"9864","DOI":"10.1073\/pnas.142298299","article-title":"Characterization of the expression of MHC proteins in human embryonic stem cells","volume":"99","author":"Drukker","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1634\/stemcells.2008-0528","article-title":"Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes","volume":"27","author":"Frenzel","year":"2009","journal-title":"Stem Cells"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0002622","article-title":"The tumorigenicity of mouse embryonic stem cells and in vitro differentiated neuronal cells is controlled by the recipients\u2019 immune response","volume":"3","author":"Dressel","year":"2008","journal-title":"PLoS ONE"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"I166","DOI":"10.1161\/CIRCULATIONAHA.104.525824","article-title":"Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium","volume":"112","author":"Swijnenburg","year":"2005","journal-title":"Circulation"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1634\/stemcells.2005-0188","article-title":"Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells","volume":"24","author":"Drukker","year":"2006","journal-title":"Stem Cells"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1096\/fj.06-6769com","article-title":"Transplantation of undifferentiated murine embryonic stem cells in the heart: Teratoma formation and immune response","volume":"21","author":"Nussbaum","year":"2007","journal-title":"FASEB J."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"582","DOI":"10.3389\/fimmu.2016.00582","article-title":"Allorecognition by T lymphocytes and allograft rejection","volume":"7","author":"Marino","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/TP.0b013e3181a19421","article-title":"Variation in MHC expression between undifferentiated mouse ES cells and ES cell-derived insulin-producing cell clusters","volume":"87","author":"Boyd","year":"2009","journal-title":"Transplantation"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1089\/scd.2006.15.707","article-title":"Undifferentiated murine embryonic stem cells cannot induce portal tolerance but may possess immune privilege secondary to reduced major histocompatibility complex antigen expression","volume":"15","author":"Magliocca","year":"2006","journal-title":"Stem Cells Dev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.4049\/jimmunol.147.8.2740","article-title":"Distinct patterns of expression of MHC class I and beta 2-microglobulin transcripts at early stages of mouse development","volume":"147","author":"Jaffe","year":"1991","journal-title":"J. Immunol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.stem.2011.01.012","article-title":"Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells","volume":"8","author":"Pearl","year":"2011","journal-title":"Cell Stem Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3727\/096368913X674639","article-title":"Characteristic expression of major histocompatibility complex and immune privilege genes in human pluripotent stem cells and their derivatives","volume":"24","author":"Chen","year":"2015","journal-title":"Cell Transplant."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1634\/stemcells.2008-0078","article-title":"Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack","volume":"26","author":"Wu","year":"2008","journal-title":"Stem Cells"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1073\/pnas.0915086107","article-title":"V Natural immunity to pluripotency antigen OCT4 in humans","volume":"107","author":"Dhodapkar","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1634\/stemcells.22-4-448","article-title":"Human embryonic stem cells possess immune-privileged properties","volume":"22","author":"Li","year":"2004","journal-title":"Stem Cells"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"12991","DOI":"10.1073\/pnas.0805802105","article-title":"Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts","volume":"105","author":"Swijnenburg","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ni1201","article-title":"Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells","volume":"6","author":"Binder","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"4803","DOI":"10.4049\/jimmunol.177.7.4803","article-title":"Complement-dependent control of teratoma formation by embryonic stem cells","volume":"177","author":"Koch","year":"2006","journal-title":"J. Immunol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3892\/ijmm.2012.1195","article-title":"Vaccination with embryonic stem cells generates effective antitumor immunity against ovarian cancer","volume":"31","author":"Zhang","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00262-010-0899-9","article-title":"Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load","volume":"59","author":"Dong","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0042289","article-title":"Vaccination with embryonic stem cells protects against lung cancer: Is a broad-spectrum prophylactic vaccine against cancer possible?","volume":"7","author":"Yaddanapudi","year":"2012","journal-title":"PLoS ONE"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.stem.2015.07.021","article-title":"Humanized mice reveal differential immunogenicity of cells derived from autologous induced pluripotent stem cells","volume":"17","author":"Zhao","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3389\/fimmu.2019.00656","article-title":"Deciphering the roles of innate lymphoid cells in cancer","volume":"10","author":"Bruchard","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.immuni.2018.03.009","article-title":"Unconventional T cell targets for cancer immunotherapy","volume":"48","author":"Godfrey","year":"2018","journal-title":"Immunity"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cell.2016.01.002","article-title":"Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells","volume":"164","author":"Dadi","year":"2016","journal-title":"Cell"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cell.2018.07.017","article-title":"Innate lymphoid cells: 10 years on","volume":"174","author":"Vivier","year":"2018","journal-title":"Cell"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"228ra37","DOI":"10.1126\/scitranslmed.3007240","article-title":"Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients","volume":"6","author":"Mlecnik","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1084\/jem.20162031","article-title":"Tissue microenvironment dictates the fate and tumor-suppressive function of type 3 ILCs","volume":"214","author":"Nussbaum","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/MOT.0b013e328309ee31","article-title":"Pathways of major histocompatibility complex allorecognition","volume":"13","author":"Afzali","year":"2008","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fimmu.2012.00279","article-title":"Tight control\u2014Decision-making during T cell-vascular endothelial cell interaction","volume":"3","author":"Firner","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_155","first-page":"1","article-title":"Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells","volume":"5","author":"Rodriguez","year":"2010","journal-title":"PLoS ONE"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1046\/j.1523-1755.1999.00751.x","article-title":"Why do we reject a graff? Role of indirect allorecognition in graft rejection","volume":"56","author":"Sayegh","year":"1999","journal-title":"Kidney Int."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/TP.0b013e318191b38b","article-title":"Differential roles of direct and indirect allorecognition pathways in the rejection of skin and corneal transplants","volume":"87","author":"Liu","year":"2009","journal-title":"Transplantation"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/00007890-199405150-00001","article-title":"Mechanisms of T cell recognition of alloantigen. The role of peptides","volume":"57","author":"Sayegh","year":"1994","journal-title":"Transplantation"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0041-1345(98)01797-7","article-title":"Indirect allorecognition is involved in both acute and chronic allograft rejection","volume":"31","author":"Fluck","year":"1999","journal-title":"Transplant. Proc."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/stem.2227","article-title":"Brief report: Immune microenvironment determines the immunogenicity of induced pluripotent stem cell derivatives","volume":"34","author":"Todorova","year":"2016","journal-title":"Stem Cells"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature11807","article-title":"Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells","volume":"494","author":"Araki","year":"2013","journal-title":"Nature"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.stem.2013.01.006","article-title":"Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells","volume":"12","author":"Guha","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.coi.2010.01.011","article-title":"Immunity to stemness genes in human cancer","volume":"22","author":"Dhodapkar","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy","volume":"204","author":"Spisek","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/0959-8049(93)90545-Q","article-title":"Immunological paradox in testicular tumours: The presence of a large number of activated T-cells despite the complete absence of MHC antigens","volume":"29","author":"Nouri","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1535-6108(03)00270-8","article-title":"Oct-3\/4 is a dose-dependent oncogenic fate determinant","volume":"4","author":"Gidekel","year":"2003","journal-title":"Cancer Cell"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"368ra171","DOI":"10.1126\/scitranslmed.aag1298","article-title":"Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions","volume":"8","author":"Rosenblatt","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.4049\/jimmunol.178.11.6840","article-title":"CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a b cell lymphoma model","volume":"178","author":"Elpek","year":"2007","journal-title":"J. Immunol."},{"key":"ref_169","first-page":"4942","article-title":"Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers","volume":"61","author":"Shin","year":"2001","journal-title":"Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s002620000154","article-title":"Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient","volume":"49","author":"Real","year":"2001","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1242\/jcs.087718","article-title":"Immunobiology of na\u00efve and genetically modified HLA-class-I-knockdown human embryonic stem cells","volume":"124","author":"Deuse","year":"2011","journal-title":"J. Cell Sci."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nature13312","article-title":"Metabolism of stromal and immune cells in health and disease","volume":"511","author":"Wong","year":"2014","journal-title":"Nature"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41573-019-0032-5","article-title":"Targeting metabolism to regulate immune responses in autoimmunity and cancer","volume":"18","author":"Patel","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cmet.2018.02.024","article-title":"Increased tumor glycolysis characterizes immune resistance to adoptive t cell therapy","volume":"27","author":"Cascone","year":"2018","journal-title":"Cell Metab."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/cc.23352","article-title":"The mitochondrial H+-ATP synthase and the lipogenic switch New core components of metabolic reprogramming in induced pluripotent stem (iPS) cells","volume":"12","author":"Cufi","year":"2013","journal-title":"Cell Cycle"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Heront-Kishi, M., Asgarova, A., Desterke, C., Chaker, D., de Go\u00ebr de Herve, M.-G., Turhan, A.G., Bennaceur-Griscelli, A., and Griscelli, F. (2020). Pharmacologically modified pluripotent stem cell-based cancer vaccines with anti-metastatic potential. bioRxiv.","DOI":"10.1101\/2020.05.27.118471"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.vaccine.2019.01.045","article-title":"Viral vector and route of administration determine the ILC and DC profiles responsible for downstream vaccine-specific immune outcomes","volume":"37","author":"Roy","year":"2019","journal-title":"Vaccine"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1089\/scd.2007.0160","article-title":"Spatial and temporal kinetics of teratoma formation from murine embryonic stem cell transplantation","volume":"16","author":"Cao","year":"2007","journal-title":"Stem Cells Dev."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3581\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:39:40Z","timestamp":1760179180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":180,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["cancers12123581"],"URL":"https:\/\/doi.org\/10.3390\/cancers12123581","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]}}}